NR3C2 and heart failure: The minerAlocorticoid Receptor antagonist Tolerability Study (ARTS) was a phase 2a clinical trial that assessed the safety and tolerability of finerenone in patients with heart failure with reduced ejection fraction and mild or moderate chronic kidney disease [128].